Status:
COMPLETED
Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
Lead Sponsor:
Chuncheon Sacred Heart Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The aim of this study was to evaluate the additive effect of trimebut...
Detailed Description
Adverse events related to the eradication medication is one of the reason of lower eradication success in the H. pylori treatment. The common adverse events related to the eradication medications area...
Eligibility Criteria
Inclusion
- Subjects who underwent upper gastrointestinal endoscopy and were proven to have H. pylori infection either by using the rapid urease test, the 13 C-urea breath test (UBT), or histological examination.
Exclusion
- Subjects who took medications as Proton pump inhibitor, Histamin-2 receptor antagonist and antibiotics,
- Subjects who underwent stomach resection
- Subjects less than 18 years of age
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04403087
Start Date
May 1 2021
End Date
July 1 2021
Last Update
July 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chuncheon Sacred Heart hospital
Chuncheon, Gangwon-do, South Korea, 24253